Renal cell carcinomaMolecular biomarkersPrognostic markersVascular endothelial growth factorTyrosine kinase inhibitorMammalian target of rapamycin inhibitorRecent advances in the biological understanding of renal cell carcinoma (RCC) have led to the identification of several molecular biomarkers with prognostic and...
Renal cell carcinoma: novel treatments for advanced disease E Huland,H Heinzer - 《Current Opinion in Urology》 被引量: 0发表: 2003年 VHL, the story of a tumour suppressor gene Early inactivation of VHL is commonly seen in clear-cell renal cell carcinoma (ccRCC), and insights gained from...
Recent advances in the biological understanding of renal cell carcinoma (RCC) have led to the identification of several molecular biomarkers with prognostic and therapeutic value. Clinical trials have proven the effectiveness of targeted therapies for advanced RCC and a growing body of work is underway...
Kidney cancer or renal cell carcinoma can be treated with nephrectomy (surgical kidney removal), chemotherapy and targeted cancer therapy.
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, cur
A major advance in renal cell carcinoma is the realisation that this disease is not one entity but rather a collection of different types of tumours, each derived from the various parts of the nephron and possessing distinct genetic characteristics, histological features, and, to some extent, clin...
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, cur
A variety of treatments are available, including radiotherapy, chemotherapy, immunotherapy and targeted therapy, but distant metastasis remains an important obstacle limiting the treatment effect in kidney renal clear cell carcinoma due to drug resistance and severe side effects [4,[6], [7], [8]]...
Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that reflects the trajectory of evolution and influences clinical prognosis. Here, we seek to elucidate how ITH and tumor evolution during immune checkpoint inhibitor (ICI) treatment can lead to therapy resistan...
Over the past 5 years, several new immunotherapy treatments have been tested for metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different immunotherapies, or of an immunotherapy with a tyrosine kinase inhibitor (TKI), h